Key Highlights
- Shares are trading up about 7.95% today, extending a rebound from Tuesday's dip.
- The board appointed Everett Cunningham as CEO, effective on or before December 15.
- Cunningham joins from Quanterix, where he served as President and CEO.
- Outgoing CEO Katherine Stueland will remain as an adviser through January 31, 2027.
- The company reaffirmed its full-year 2026 financial guidance.
GeneDx Holdings (NASDAQ:WGS) shares are trading higher today after the company announced that its board has appointed Everett Cunningham as Chief Executive Officer, effective on or before December 15, 2026. GeneDx is a genomics company specializing in clinical exome and genome sequencing for pediatric and rare disease diagnosis, supported by GeneDx Infinity, one of the world's largest rare disease genomic datasets. Cunningham succeeds Katherine Stueland, who will step down as CEO and board member when he joins, remaining with the company in an advisory capacity through January 31, 2027.
Incoming CEO Brings More Than 35 Years of Diagnostics Experience
Cunningham joins GeneDx from Quanterix (NASDAQ:QTRX), where he most recently served as President and CEO, and brings more than 35 years of commercial Leadership experience across diagnostics, genomics, and pharmaceuticals, including prior senior roles at Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics, and Pfizer. The board chairman said Cunningham is uniquely positioned to move exome and genome sequencing from early adoption toward standard of care.
Outgoing CEO Credited With Five-Year Transformation
The board thanked outgoing CEO Stueland for leading the company's transformation into an independent, profitable Business over the past five and a half years, including its combination with Sema4 and subsequent Revenue growth. Mark Gardner will continue serving as President, reporting to Cunningham once the transition is complete.
Full-Year Guidance Reaffirmed Alongside the Leadership Change
The company reaffirmed its full-year 2026 financial guidance, as provided on November 9 in connection with its third-quarter results, signaling that the leadership transition is not expected to affect near-term financial expectations.
What Investors Are Watching Through the Transition
With the handoff expected on or before December 15, investors are likely to focus on how smoothly the transition proceeds and any early commentary from Cunningham on his priorities for accelerating adoption of the company's genomic testing platform.






Please wait processing your request...